Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
1.950
-0.050 (-2.50%)
At close: Mar 6, 2026, 4:00 PM EST
1.960
+0.010 (0.51%)
After-hours: Mar 6, 2026, 7:52 PM EST
Genprex Employees
Genprex had 16 employees as of December 31, 2024. The number of employees decreased by 10 or -38.46% compared to the previous year.
Employees
16
Change (1Y)
-10
Growth (1Y)
-38.46%
Revenue / Employee
n/a
Profits / Employee
-$1,289,939
Market Cap
4.52M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| GeoVax Labs | 17 |
| VivoSim Labs | 14 |
| BioRestorative Therapies | 11 |
| Revelation Biosciences | 9 |
| MetaVia | 9 |
| Indaptus Therapeutics | 7 |
| Galmed Pharmaceuticals | 6 |
| Silo Pharma | 3 |
GNPX News
- 12 days ago - Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer - PRNewsWire
- 25 days ago - Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - PRNewsWire
- 2 months ago - Genprex Provides Clinical Update on Diabetes Gene Therapy Program - PRNewsWire
- 2 months ago - Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies - PRNewsWire
- 3 months ago - Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer - PRNewsWire
- 3 months ago - Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials - PRNewsWire
- 3 months ago - Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - PRNewsWire
- 4 months ago - Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer - PRNewsWire